Skip to main content

AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 14, 2025.

via HealthDay

FRIDAY, March 14, 2025 -- Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off treatment, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 7 to 11 in Orlando, Florida.

David Rosmarin, M.D., of the Indiana University School of Medicine in Indianapolis, and colleagues conducted a 48-week open-label, long-term extension study (ADORING 3) evaluating tapinarof in 728 eligible adults and children aged 2 years or older with AD. Patients entering ADORING 3 with Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) ≥1 received tapinarof until vIGA-AD = 0 (completely clear skin). Those entering or achieving vIGA-AD = 0 discontinued tapinarof and were assessed for maintenance while off treatment. Those whose AD returned to vIGA-AD ≥2 were retreated until vIGA-AD = 0.

The researchers found that at the end of the first treatment-free interval (mean, 79.8 days), 84.0 percent of patients had vIGA-AD = 2, a mean Eczema Area and Severity Index score of 3.4, and a mean weekly Peak Pruritus-Numerical Rating Scale score of 2.9. At the end of subsequent treatment-free intervals, similar low disease activity was seen. After about 80 consecutive days off treatment, a high proportion of patients demonstrated low disease activity, including itch.

"These data reinforce the efficacy of Vtama cream in atopic dermatitis, including the durability of effect among patients in the study, including children as young as 2 years old," Juan Camilo Arjona Ferreira, M.D., head of research and development and chief medical officer at Organon, said in a statement.

The study was funded by Dermavant Sciences (an Organon Company), which manufactures tapinarof.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Novel Treatments Recommended for Management of Atopic Dermatitis in Adults

FRIDAY, July 25, 2025 -- In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was...

High Dietary Inflammatory Index Tied to Increased Prevalence of Eczema

TUESDAY, July 15, 2025 -- A high dietary inflammatory index (DII), which quantifies the inflammatory potential of diet, is associated with increased prevalence of atopic...

Atopic Dermatitis May Be Linked to Increased Risk for CKD

TUESDAY, July 15, 2025 -- Atopic dermatitis (AD) was associated with an increased risk for chronic kidney disease (CKD) in an Asian population, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.